Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Dostarlimab||Phase I||Actionable||In a Phase I trial, Dostarlimab (TSR-042) demonstrated safety and preliminary efficacy, resulted in partial response in 9.5% (2/21) and stable disease in 23.8% (5.21) of patients with advanced solid tumors (Annals of Oncology (2017) 28 (suppl_5): v403-v427. Abstract # 1185P; NCT02715284).||detail...|
|PubMed Id||Reference Title||Details|
|Safety, pharmacodynamic, and pharmacokinetic profile of TSR-042, an anti–PD–1 monoclonal antibody, in patients (pts) with advanced solid tumors||Full reference...|